Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
RVL Pharmaceuticals plc RVLP
$0.90
+$0.03 (3.45%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
82450399.00000000
-
week52high
2.99
-
week52low
0.73
-
Revenue
49721000
-
P/E TTM
-2
-
Beta
1.09560900
-
EPS
-0.60000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 23 дек 2021 г. | |
| Cantor Fitzgerald | Overweight | 24 сент 2021 г. | |
| Barclays | Overweight | Overweight | 25 окт 2022 г. |
| RBC Capital | Outperform | Outperform | 17 мар 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Avista Capital Partners III GP, L.P. | D | 0 | 1032995 | 27 янв 2023 г. |
| Venkataraman Sriram | D | 0 | 1032995 | 27 янв 2023 г. |
| Burgstahler David F | D | 0 | 1032995 | 27 янв 2023 г. |
| Schaub James | D | 530412 | 9608 | 24 янв 2023 г. |
| Klein Christopher | D | 186020 | 9608 | 24 янв 2023 г. |
| Lask Alisa | A | 84557 | 75000 | 10 авг 2022 г. |
| Avista Healthcare Partners, L.P. | A | 23730864 | 8000000 | 08 авг 2022 г. |
| Venkataraman Sriram | A | 23730864 | 8000000 | 08 авг 2022 г. |
| Burgstahler David F | A | 23730864 | 8000000 | 08 авг 2022 г. |
| MARKISON BRIAN A | A | 2976020 | 850000 | 08 авг 2022 г. |
Новостная лента
RVL Pharmaceuticals: A First 'Look'
Seeking Alpha
30 дек 2022 г. в 15:30
Today we take our first look at RVL Pharmaceuticals plc, a small ocular-focused concern. RVL Pharmaceuticals plc recently launched the first and only FDA-approved ophthalmic solution to treat low-lying eyelids in adults.
RVL Pharmaceuticals plc (RVLP) Q3 2022 Earnings Call Transcript
Seeking Alpha
10 ноя 2022 г. в 22:21
RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Lisa Wilson – Investor Relations Brian Markison – Chief Executive Officer JD Schaub – Chief Operating Officer Mike DePetris – Interim Chief Financial Officer Conference Call Participants Louise Chen – Cantor Fitzgerald Douglas Tsao – H.C Wainwright John Vandermosten – Zacks Operator Good day, everyone. My name is Chelsea, and I'll be your conference operator.
RVL Pharmaceuticals PLC (RVLP) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
11 авг 2022 г. в 12:03
RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 20.83% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
RVL Pharmaceuticals plc (RVLP) CEO Brian Markison on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
11 авг 2022 г. в 12:01
RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Lisa Wilson - IR Brian Markison - CEO Mike DePetris - Interim CFO JD Schaub - COO Conference Call Participants Louise Chen - Cantor Douglas Tsao - H.C Wainwright Michaela Diverio - Barclays Operator Good day and thank you for standing by. Welcome to the RVL Pharmaceuticals Second Quarter 2022 Earnings Call.
RVL Pharmaceuticals plc to Present at Upcoming Conferences
GlobeNewsWire
16 мая 2022 г. в 06:50
BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at two upcoming conferences as follows: